Marinus Pharmaceuticals Investor Relations Material
Latest events
Investor & Analyst 2024
Marinus Pharmaceuticals
Investor Presentation
12 Nov, 2024
Q3 2024
12 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Marinus Pharmaceuticals Inc
Access all reports
Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy with a focus on rare and orphan seizures, as well as neuropsychiatric disorders in the United States.
Key slides for Marinus Pharmaceuticals Inc
Investor & Analyst 2024
Marinus Pharmaceuticals Inc
Investor & Analyst 2024
Marinus Pharmaceuticals Inc
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
MRNS
Country
🇺🇸 United States